Journals / The Journal of Pediatric Research / 2017 / Cilt: 4 - Sayı: 1

Antipsychotic Drugs Rechallenge in Multi-antipsychotic Drug Induced Atypical Neuroleptic Malignant Syndrome: A Case of Cotard's Syndrome

Çoklu Antipsikotik İlaç Kullanımı ile Tetiklenen Atipik Nöroleptik Malign Sendromda Antipsikotik İlaç Başlama Güçlükleri: Cotard Sendromu Olgusu

Pages
31–34
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

By presenting this case, we aim to discuss the differential diagnosis and treatment plan of a patient with catatonia and Cotard's syndrome, which were noted after NMS, in light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal idiosyncratic reaction to neuroleptics and characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia.
📊
Key Findings & Data:Cotard's syndrome is characterized by the appearance of nihilistic delusions concerning one's own body or life.
💡
Conclusion & Impact:By presenting this case, we aim to discuss the differential diagnosis and treatment plan of a patient with catatonia and Cotard's syndrome, which were noted after NMS, in light of the literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal idiosyncratic reaction to neuroleptics and characterized by a distinctive clinical syndrome of mental status change, rigidity, fever, and dysautonomia. Cotard's syndrome is characterized by the appearance of nihilistic delusions concerning one's own body or life. By presenting this case, we aim to discuss the differential diagnosis and treatment plan of a patient with catatonia and Cotard's syndrome, which were noted after NMS, in light of the literature.

Özet

Nöroleptik malign sendrom (NMS), nöroleptik ajanların kullanımıyla ortaya çıkan, bilinçte değişiklikler, rijidite, ateş yüksekliği ve otonomik değişiklikler ile karakterize olan, nadir fakat ölümcül bir idiosenkratik reaksiyondur. Cotard sendromu ise, kişinin bedeni ya da yaşamı ile ilişkili nihilistik sanrılarla karakterize bir sendromdur. Bu olgu sunumu ile, NMS sonrasında katatoni ve Cotard sendromu gelişen hastada, ayırıcı tanıları ve tedavi planını literatür eşliğinde tartışmayı amaçladık.

🔖

Cite This Article

YILMAZ, H., ÖZBARAN, N. B., KÖSE, S. (2017). Antipsychotic Drugs Rechallenge in Multi-antipsychotic Drug Induced Atypical Neuroleptic Malignant Syndrome: A Case of Cotard's Syndrome. The Journal of Pediatric Research, Cilt: 4 - Sayı: 1, 31–34. https://ajindex.com/articles/362966

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35
  2. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6
  3. Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J. Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38:187-94
  4. Vihang N. Vahia. Diagnostic and statistical manual of mental disorders 5: A quick glance. Indian J Psychiatry 2013;55:220- 3
  5. Bond AG. Antipsychotic Rechallenge After Neuroleptic Malignant Syndrome with Catatonic Features. 2011:1-28
  6. Picard LS, Lindsay S, Strawn JR, Kaneria RM, Patel NC, Keck PE. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008;28:530-5
  7. Copeland WE, Angold A, Costello EJ, Egger H. Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. Am J Psychiatry 2013;170:173- 9
  8. Keck PE. Risk Factors for Neuroleptic Malignant Syndrome. Arch Gen Psychiatry 1989;46:914
  9. Nisijima K, Ishiguro T. Neuroleptic malignant syndrome: A study of CSF monoamine metabolism. Biol Psychiatry 1990;27:280-8
  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th.; 2013. doi:10.1176/appi. books
  11. Koch M, Chandragiri S, Rizvi S, Petrides G, Francis A. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry 2000;41:73-5
  12. Trollor J, Sachdev P. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999;33:650-9
  13. Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11:R4 14. Debruyne H, Portzky M, Peremans K, Audenaert K. Cotard's Syndrome. Mind&Brain 2011;2:67-72
  14. Chiu H. Cotard's syndrome in psychogeriatric patients in Hong Kong. Gen Hosp Psychiatry 1995;17:54-5
  15. Debruyne H, Portzky M, Van den Eynde F, Audenaert K. Cotard's syndrome: A review. Curr Psychiatry Rep 2009;11:197-202
  16. Consoli A, Soultanian C, Tanguy ML, et al. Cotard's syndrome in adolescents and young adults is associated with an increased risk of bipolar disorder. Bipolar Disord 2007;9:665-8
  17. Cohen D, Cottias C, Basquin M. Cotard's syndrome in a 15-year-old girl. Acta Psychiatr Scand 1997;95:164-5
  18. Berrios GE, Luque R. Cotard's syndrome: analysis of 100 cases. Acta Psychiatr Scand 1995;91:185-8
  19. Yamada K, Katsurag